Sarepta Therapeutics, Inc. (SRPT)
21.33
+0.30
(+1.43%)
USD |
NASDAQ |
Sep 01, 16:00
21.44
+0.11
(+0.52%)
Pre-Market: 09:10
Sarepta Therapeutics Research and Development Expense (Annual) : 1.493B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.493B |
| December 31, 2024 | 778.47M |
| December 31, 2023 | 844.38M |
| December 31, 2022 | 839.38M |
| December 31, 2021 | 743.39M |
| December 31, 2020 | 704.19M |
| December 31, 2019 | 560.71M |
| December 31, 2018 | 397.94M |
| December 31, 2017 | 166.52M |
| December 31, 2016 | 186.26M |
| December 31, 2015 | 146.39M |
| December 31, 2014 | 94.12M |
| December 31, 2013 | 71.71M |
| Date | Value |
|---|---|
| December 31, 2012 | 52.33M |
| December 31, 2011 | 66.31M |
| December 31, 2010 | 35.97M |
| December 31, 2009 | 23.02M |
| December 31, 2008 | 27.53M |
| December 31, 2007 | 32.75M |
| December 31, 2006 | 23.26M |
| December 31, 2005 | 15.12M |
| December 31, 2004 | 18.85M |
| December 31, 2003 | 13.80M |
| December 31, 2002 | 21.08M |
| December 31, 2001 | 12.20M |
| December 31, 2000 | 9.268M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Moderna, Inc. | 2.917B |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| ImmunityBio, Inc. | 216.56M |
| X4 Pharmaceuticals, Inc. | 72.22M |
| MapLight Therapeutics, Inc. | 138.35M |